Discordance rate between radiolabelled choline PET/CT and bone scintigraphy in detecting bone metastases in patients with prostate cancer: A meta-analysis

被引：2
作者：
Treglia G. [1 ]
Vigneri C. [2 ]
Sadeghi R. [3 ]
Evangelista L. [4 ]
Ceriani L. [1 ]
Giovanella L. [1 ]
机构：
[1] Department of Nuclear Medicine and PET/CT Center, Oncology Institute of Southern Switzerland, via Ospedale, 12, Bellinzona
[2] Centro Polidiagnostico Medicina Nucleare, C.P.M.N. srl, Catania
[3] Nuclear Medicine Research Center, Mashhad University of Medical Sciences, Mashhad
[4] Radiotherapy and Nuclear Medicine Unit, Oncological Institute of Veneto IOV-IRCCS, Padua
来源：
Clinical and Translational Imaging | 2015年 / 3卷 / 2期
关键词：
Bone metastasis; Bone scintigraphy; Choline; Positron emission tomography; Prostate cancer;
D O I：
10.1007/s40336-015-0107-1
中图分类号：
学科分类号：
摘要：
The objective of the study was to systematically review published data and perform a meta-analysis about the discordance rate between radiolabelled choline PET/CT and bone scintigraphy (BS) in detecting bone metastases in patients with prostate cancer (PCa). A comprehensive literature search of studies or subsets of studies published through November 2014 including information on the comparison among radiolabelled choline PET/CT and bone scintigraphy in PCa patients was carried out. A meta-analysis was performed in order to calculate the pooled discordance rate among these methods in detecting bone metastases on a per patient-based analysis. Twelve articles were selected. The pooled discordance rate among radiolabelled choline PET/CT and BS in detecting bone metastases was 10.9 % (95 % confidence interval 6.3–16.7 %). Discordant findings were due to radiolabelled choline positive and BS negative or inconclusive findings, but BS positive and radiolabelled choline-negative findings also occurred. We discuss the possible causes of discordant findings. Discordance rate between radiolabelled choline PET/CT and BS in detecting bone metastases in PCa patients is not negligible and both methods are useful in this setting. © 2015, Italian Association of Nuclear Medicine and Molecular Imaging.
引用
收藏
页码：133 / 140
页数：7
相关论文
共 41 条
  • [1] Marta G.N., Hanna S.A., Fernandes da Silva J.L., Carvalho Hde A., Screening for prostate cancer: an updated review, Expert Rev Anticancer Ther, 13, pp. 101-108, (2013)
  • [2] Heidenreich A., Bastian P.J., Bellmunt J., Bolla M., Joniau S., van der Kwast T., Mason M., Matveev V., Wiegel T., Zattoni F., Mottet N., European Association of Urology, EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent-update 2013, Eur Urol, 65, pp. 124-137, (2014)
  • [3] Heidenreich A., Bastian P.J., Bellmunt J., Bolla M., Joniau S., van der Kwast T., Mason M., Matveev V., Wiegel T., Zattoni F., Mottet N., European Association of Urology, EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer, Eur Urol, 65, pp. 467-479, (2014)
  • [4] Prostate Cancer, Version, (2015)
  • [5] Rigaud J., Tiguert R., Le Normand L., Karam G., Glemain P., Buzelin J.M., Bouchot O., Prognostic value of bone scan in patients with metastatic prostate cancer treated initially with androgen deprivation therapy, J Urol, 168, pp. 1423-1426, (2002)
  • [6] Caldarella C., Treglia G., Giordano A., Giovanella L., When to perform positron emission tomography/computed tomography or radionuclide bone scan in patients with recently diagnosed prostate cancer, Cancer Manag Res, 5, pp. 123-131, (2013)
  • [7] Evangelista L., Cervino A.R., Burei M., Gregianin M., Saladini G., Marzola M.C., Chondrogianis S., Rubello D., Comparative studies of radiolabeled choline positron emission tomography, histology of primary tumor and other imaging modalities in prostate cancer: a systematic review and meta-analysis, Clin Transl Imaging, 1, pp. 99-109, (2013)
  • [8] Shen G., Deng H., Hu S., Jia Z., Comparison of choline-PET/CT, MRI, SPECT, and bone scintigraphy in the diagnosis of bone metastases in patients with prostate cancer: a meta-analysis, Skeletal Radiol, 43, pp. 1503-1513, (2014)
  • [9] von Eyben F.E., Kairemo K., Meta-analysis of (11)C-choline and (18)F-choline PET/CT for management of patients with prostate cancer, Nucl Med Commun, 35, pp. 221-230, (2014)
  • [10] Umbehr M.H., Muntener M., Hany T., Sulser T., Bachmann L.M., The role of 11C-choline and 18F-fluorocholine positron emission tomography (PET) and PET/CT in prostate cancer: a systematic review and meta-analysis, Eur Urol, 64, pp. 106-117, (2013)
12345